LIP-01
Dietary Supplementcomparison of different dosages of natural health product
NCT Number: NCT00966225
The purpose of this study is to determine a safe and tolerable dose of LIP-01
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 1
The Northern Alberta Clinical Trials and Research Centre, Edmonton, Alberta, Canada
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
comparison of different dosages of natural health product
Time frame: 12 weeks
Afexa Life Sciences Inc
Industry
An Open-label Dose-finding Study of LIP-01 in Otherwise Healthy Individuals With Hypercholesterolemia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07737067
Arthrosclerosis, Dyslipidemias
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT05694260
Dyslipidemias, Hypercholesterolemia
Los Angeles, California, United States
View Trial DetailsNCT07655960
Dyslipidemia, Dyslipidemias
Seoul, South Korea
View Trial DetailsNCT02579655
Brain Diseases, Cardiovascular Diseases
Calgary, Alberta, Canada
View Trial Details